Monitoring the impact of a national HPV vaccination program in Japan (MINT Study): rationale, design and methods

MINT Study Group

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

We have developed a collaborative hospital-based approach to monitoring the impact of a human papillomavirus vaccine on cervical cancer, its precursor lesions and human papillomavirus type-specific prevalence in Japan. The monitoring will be conducted for a total period of 21 years on women aged <40 who are newly diagnosed with invasive cervical cancer, cervical intraepithelial neoplasia or adenocarcinoma in situ at 21 participating institutes. Women are monitored to determine their vaccine history and will be human papillomavirus-genotyped each year. The primary endpoint is the human papillomavirus16/human papillomavirus18-positive rate in women aged 16-25 who are diagnosed with invasive cervical cancer, cervical intraepithelial neoplasia grade 2/3 and adenocarcinoma in situ. The major secondary endpoints are the number of women aged <40 who are diagnosed with invasive cervical cancer, cervical intraepithelial neoplasia grade 2/3 and adenocarcinoma in situ, the human papillomavirus type-specific prevalence, and the number of deaths from invasive cervical cancer in women aged <40. Long-term surveillance for human papillomavirus-associated cervical diseases in young females is important for the development of future strategies for cervical cancer prevention in Japan.

Original languageEnglish
Pages (from-to)1000-1003
Number of pages4
JournalJapanese Journal of Clinical Oncology
Volume44
Issue number10
DOIs
Publication statusPublished - Oct 1 2014

Fingerprint

Uterine Cervical Neoplasms
Japan
Vaccination
Cervical Intraepithelial Neoplasia
Papillomavirus Vaccines
Vaccines
History
Adenocarcinoma in Situ

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Monitoring the impact of a national HPV vaccination program in Japan (MINT Study) : rationale, design and methods. / MINT Study Group.

In: Japanese Journal of Clinical Oncology, Vol. 44, No. 10, 01.10.2014, p. 1000-1003.

Research output: Contribution to journalArticle

@article{0ef88d1053184bbb82fd6fb7fce99e2f,
title = "Monitoring the impact of a national HPV vaccination program in Japan (MINT Study): rationale, design and methods",
abstract = "We have developed a collaborative hospital-based approach to monitoring the impact of a human papillomavirus vaccine on cervical cancer, its precursor lesions and human papillomavirus type-specific prevalence in Japan. The monitoring will be conducted for a total period of 21 years on women aged <40 who are newly diagnosed with invasive cervical cancer, cervical intraepithelial neoplasia or adenocarcinoma in situ at 21 participating institutes. Women are monitored to determine their vaccine history and will be human papillomavirus-genotyped each year. The primary endpoint is the human papillomavirus16/human papillomavirus18-positive rate in women aged 16-25 who are diagnosed with invasive cervical cancer, cervical intraepithelial neoplasia grade 2/3 and adenocarcinoma in situ. The major secondary endpoints are the number of women aged <40 who are diagnosed with invasive cervical cancer, cervical intraepithelial neoplasia grade 2/3 and adenocarcinoma in situ, the human papillomavirus type-specific prevalence, and the number of deaths from invasive cervical cancer in women aged <40. Long-term surveillance for human papillomavirus-associated cervical diseases in young females is important for the development of future strategies for cervical cancer prevention in Japan.",
author = "{MINT Study Group} and Koji Matsumoto and Nobuo Yaegashi and Takashi Iwata and Kazuya Ariyoshi and Kiyoshi Fujiwara and Yuko Shiroyama and Tomoka Usami and Yoshiaki Kawano and Koji Horie and Kouichiro Kawano and Kiichiro Noda and Hiroyuki Yoshikawa",
year = "2014",
month = "10",
day = "1",
doi = "10.1093/jjco/hyu097",
language = "English",
volume = "44",
pages = "1000--1003",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Monitoring the impact of a national HPV vaccination program in Japan (MINT Study)

T2 - rationale, design and methods

AU - MINT Study Group

AU - Matsumoto, Koji

AU - Yaegashi, Nobuo

AU - Iwata, Takashi

AU - Ariyoshi, Kazuya

AU - Fujiwara, Kiyoshi

AU - Shiroyama, Yuko

AU - Usami, Tomoka

AU - Kawano, Yoshiaki

AU - Horie, Koji

AU - Kawano, Kouichiro

AU - Noda, Kiichiro

AU - Yoshikawa, Hiroyuki

PY - 2014/10/1

Y1 - 2014/10/1

N2 - We have developed a collaborative hospital-based approach to monitoring the impact of a human papillomavirus vaccine on cervical cancer, its precursor lesions and human papillomavirus type-specific prevalence in Japan. The monitoring will be conducted for a total period of 21 years on women aged <40 who are newly diagnosed with invasive cervical cancer, cervical intraepithelial neoplasia or adenocarcinoma in situ at 21 participating institutes. Women are monitored to determine their vaccine history and will be human papillomavirus-genotyped each year. The primary endpoint is the human papillomavirus16/human papillomavirus18-positive rate in women aged 16-25 who are diagnosed with invasive cervical cancer, cervical intraepithelial neoplasia grade 2/3 and adenocarcinoma in situ. The major secondary endpoints are the number of women aged <40 who are diagnosed with invasive cervical cancer, cervical intraepithelial neoplasia grade 2/3 and adenocarcinoma in situ, the human papillomavirus type-specific prevalence, and the number of deaths from invasive cervical cancer in women aged <40. Long-term surveillance for human papillomavirus-associated cervical diseases in young females is important for the development of future strategies for cervical cancer prevention in Japan.

AB - We have developed a collaborative hospital-based approach to monitoring the impact of a human papillomavirus vaccine on cervical cancer, its precursor lesions and human papillomavirus type-specific prevalence in Japan. The monitoring will be conducted for a total period of 21 years on women aged <40 who are newly diagnosed with invasive cervical cancer, cervical intraepithelial neoplasia or adenocarcinoma in situ at 21 participating institutes. Women are monitored to determine their vaccine history and will be human papillomavirus-genotyped each year. The primary endpoint is the human papillomavirus16/human papillomavirus18-positive rate in women aged 16-25 who are diagnosed with invasive cervical cancer, cervical intraepithelial neoplasia grade 2/3 and adenocarcinoma in situ. The major secondary endpoints are the number of women aged <40 who are diagnosed with invasive cervical cancer, cervical intraepithelial neoplasia grade 2/3 and adenocarcinoma in situ, the human papillomavirus type-specific prevalence, and the number of deaths from invasive cervical cancer in women aged <40. Long-term surveillance for human papillomavirus-associated cervical diseases in young females is important for the development of future strategies for cervical cancer prevention in Japan.

UR - http://www.scopus.com/inward/record.url?scp=84922392066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922392066&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyu097

DO - 10.1093/jjco/hyu097

M3 - Article

C2 - 25098705

AN - SCOPUS:84922392066

VL - 44

SP - 1000

EP - 1003

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 10

ER -